Tag: Elizabeth A Douglas

Poster-Disease-modifying Therapy

Is There ‘Wearing Off’ with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).

Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....

Read More

Poster-Disease-modifying Therapy

Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for treatment of relapsing remitting (RRMS) and primary...

Read More